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DJ-1 interactions with a-synuclein attenuate
aggregation and cellular toxicity in models of
Parkinson’s disease
L Zondler1, L Miller-Fleming2,3, M Repici3, S Gonc¸alves2, S Tenreiro2, R Rosado-Ramos2, C Betzer4, KR Straatman5, PH Jensen4,
F Giorgini*,3 and TF Outeiro*,1,2
Parkinson’s disease (PD) is a devastating neurodegenerative disorder characterized by the loss of neurons in the substantia
nigra pars compacta and the presence of Lewy bodies in surviving neurons. These intracellular protein inclusions are primarily
composed of misfolded a-synuclein (aSyn), which has also been genetically linked to familial and sporadic forms of PD. DJ-1 is a
small ubiquitously expressed protein implicated in several pathways associated with PD pathogenesis. Although mutations in
the gene encoding DJ-1 lead to familial early-onset PD, the exact mechanisms responsible for its role in PD pathogenesis are still
elusive. Previous work has found that DJ-1 – which has protein chaperone-like activity – modulates aSyn aggregation. Here, we
investigated possible physical interactions between aSyn and DJ-1 and any consequent functional and pathological relevance.
We found that DJ-1 interacts directly with aSyn monomers and oligomers in vitro, and that this also occurs in living cells.
Notably, several PD-causing mutations in DJ-1 constrain this interaction. In addition, we found that overexpression of DJ-1
reduces aSyn dimerization, whereas mutant forms of DJ-1 impair this process. Finally, we found that human DJ-1 as well as yeast
orthologs of DJ-1 reversed aSyn-dependent cellular toxicity in Saccharomyces cerevisiae. Taken together, these data suggest
that direct interactions between DJ-1 and aSyn constitute the basis for a neuroprotective mechanism and that familial mutations
in DJ-1 may contribute to PD by disrupting these interactions.
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Parkinson’s disease (PD) is a fatal neurodegenerative
disease characterized by the loss of neurons in the substantia
nigra pars compacta. Although most cases of PD are
sporadic, several rare genetic forms of the disease have
been identified that have contributed greatly to our
understanding of the mechanisms underlying disease
pathogenesis. Misfolded a-synuclein (aSyn) is the main
protein component of Lewy bodies (LBs) – the primary
pathological hallmark of PD1 – and aSyn has also been
genetically linked to both familial and idiopathic forms
of PD.2,3 Misfolded aSyn protein assemblies range from
monomers, oligomers and protofibrils, to fibrils and, finally, to
inclusion bodies,4 with precursor oligomeric forms of aSyn
apparently being more toxic than larger species.5 The
physiological role of aSyn remains poorly understood, but it
is thought to be associated with synaptic function/plasticity,
cell differentiation and vesicular trafficking.6 aSyn dysfunction
has been associated with many cellular effects, including
proteasome impairment,7 disruption of endoplasmic reticulum-
to-Golgi trafficking,7,8 increased production of reactive oxygen
species (ROS) and mitochondrial dysfunction.9,10 On this
evidence, several models of PD have been developed that
overexpress wild-type or familial mutant versions of aSyn in
organisms such as yeast, C. elegans, fruit flies and mice.2
Mutations in the PARK7 gene account for B1–2%
of early-onset recessive PD,2,11 characterized by
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levodopa-responsive parkinsonism. PARK7 encodes for
DJ-1, a small conserved ubiquitously expressed protein of
189 residues primarily localized in the cytoplasm, but also
found in the nucleus and associated with mitochondria.12–14
Crystallography has revealed that DJ-1 is a homodimer, which
appears to be critical for its normal physiological function.15–17
A diverse set of potential functions have been suggested for
DJ-1, including roles as an oxidative stress sensor (via a
cysteine residue at position 106, C106), a protein chaperone,
a protease, an RNA-binding protein, a transcription regulator,
a regulator of mitochondria function and a regulator of
autophagy.18 It is unclear which, if any, of these processes
underlie DJ-1-dependent pathogenesis in PD.
Previous studies reported that DJ-1 can modulate the
aggregation and toxicity of aSyn.19–21 Here, we investigated
this relationship further and found that direct interactions
between DJ-1 and monomeric/oligomeric aSyn are likely to
underlie this process. Furthermore, we observed that familial
PD mutations disrupt the interaction between DJ-1 and aSyn
and abrogate the protective effects of DJ-1. In total, our work
supports enhanced DJ-1 activity as an important target for
therapeutic intervention in PD.
Results
DJ-1 binds monomeric and oligomeric aSyn
in vitro. Although previous studies found that DJ-1 can
modulate aSyn aggregation and cytotoxicity,22 the nature of
the possible physical interaction underlying this process is
unknown. Thus, we sought to shed light into the interplay
between the two proteins. To investigate whether an
interaction between endogenous DJ-1 and aSyn is detected
in the mouse brain, we generated C57BL/6 wild-type (WT)
mouse brain homogenate and performed co-immunoprecipi-
tation with anti-aSyn antibodies (Figure 1a). An interaction
between DJ-1 and aSyn was detected indicating that DJ-1
and aSyn can specifically interact with each other at
endogenous concentrations in the brain (Figure 1a).
Next, to determine if the interaction between DJ-1 and aSyn
depends upon the aSyn aggregation species, we isolated
purified aSyn monomers and oligomers as previously
described,23 and incubated these preparations with extracts
from HEK293 cells expressing myc-tagged DJ-1. Co-immu-
noprecipitation with anti-aSyn antibodies showed that both
monomeric and oligomeric forms of aSyn interacted with DJ-1
with equivalent efficiencies (Figure 1b). These data indicate
that DJ-1 physically interacts with soluble monomeric and
oligomeric forms of aSyn in vitro.
DJ-1 interacts with aSyn in living cells. As DJ-1 can bind
monomeric and oligomeric forms of aSyn in vitro, we next
explored the interaction between the two proteins in living
cells using bimolecular fluorescence complementation
(BiFC), a powerful approach used extensively by our
groups.5,17 BiFC takes advantage of the reconstitution of
non-fluorescent fragments of fluorescent proteins (GFP,
RFP, Venus, etc.) to study protein–protein interactions in
living cells.24 In this study, BiFC constructs encoding either
DJ-1 or aSyn tagged with halves of GFP or Venus were
co-transfected into HEK293 cells (Figure 2). aSyn dimerization
can be preferentially detected using constructs in an
antiparallel orientation in the BiFC assay5 with the N-terminal
portion of GFP located at the N-terminus of aSyn and the
C-terminal portion of GFP at the C-terminus of aSyn. Here,
we utilized fusions of aSyn with fragments of Venus, because
of the improved fluorescence emission of this protein
compared with GFP.25 DJ-1 is known to form homodimers16,26
and we previously characterized this dimerization in
living cells using the BiFC assay.17 For the current study,
we took advantage of the previously employed DJ-1 BiFC
constructs, which encode DJ-1 tagged at its C-terminus with
GFP or CFP halves (DJ-1-CFPC and DJ-1-GFPN; Figure 2).
Fluorophore reconstitution has been shown to also occur for
the combinations of Venus and GFP or CFP, respectively.25
To quantify the BiFC efficiency between DJ-1 and aSyn, we
normalized the Venus/GFP emissions by the emissions of
RFP or mCherry produced from a co-transfected expression
plasmid. After subtraction of the background fluorescence,
the intensity ratios between GFP and RFP fluorescence were
calculated for every cell positive for red fluorescence, as
previously described.17 Homodimeric interaction of DJ-1 or
aSyn was confirmed by co-transfection of the two DJ-1 WT
constructs and the two aSyn constructs, respectively (Figures
2b and c). Transfection of only one of the two BiFC constructs
or the empty vector (pcDNA3.1þ ) did not lead to emission of
green fluorescence (Figure 2c), whereas co-transfection of
aSyn (VN-Syn) and DJ-1 (DJ-1-CFPC) BiFC constructs
resulted in reconstitution of the fluorophores, indicating a
direct interaction between these two proteins in living cells
(Figures 2b and c). For the combination of Syn-VC and DJ-1-
GFPN, no fluorophore reconstitution was observed (Figures
2b and c), indicating that the interaction between DJ-1 and
aSyn can only be detected when the tags are present in a
specific orientation, as previously observed for other proteins
in BiFC experiments.5 Importantly, this result also confirms
the specificity of the interaction, because the two fragments of
the fluorescent proteins are present in the same cell but do not
reconstitute the fluorophore if the orientation is not adequate.
Expression of the DJ-1 and aSyn BiFC constructs was
confirmed by immunoblotting for each experiment
(Figure 2d). The reduced expression of Syn-VC construct
compared to that of VN-Syn construct has been previously
Figure 1 DJ-1 binds monomeric and oligomeric aSyn in vitro. (a) Co-
immunoprecipitation of aSyn and DJ-1 in mouse brain homogenate demonstrates
that DJ-1 and aSyn interact at endogenous levels. An isotype IgG control was
performed to confirm the specificity of the interaction. One representative blot of
three replicates is shown. (b) Co-immunoprecipitation of monomeric (mono) and
oligomeric (oligo) aSyn with DJ-1 from lysates of DJ-1 overexpressing cells
demonstrates that DJ-1 can bind both monomeric and oligomeric aSyn species
in vitro. PBS instead of aSyn mixed with the lysate was used as negative control.
The input lane is 2% of the sample prior to immunoprecipitation. One representative
blot of three replicates is shown
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reported,5 and is likely because of the effects of the location of
the tag on the protein. However, as shown for the VN-Syn/
Syn-VC combination, this does not constrain the BiFC signal.
Thus, our results indicate that DJ-1 and aSyn can indeed
interact – likely directly, given the nature of the BiFC assay – in
living cells.
Familial PD mutations abrogate interactions between
DJ-1 and aSyn. To investigate whether the interaction
between DJ-1 and aSyn was influenced by PD-causing
mutations in one of the partners, HEK293 cells were co-
transfected with combinations of WT VN-Syn and familial
mutant DJ-1-CFPC constructs or familial mutant constructs
of VN-Syn with WT DJ-1-CFPC, respectively. Quantification
of the BiFC efficiency was performed as described above for
each BiFC combination. The DJ-1 mutants L166P, M26I,
L10P and P158D led to a dramatic reduction in the BiFC
signal, thus indicating that the interaction with aSyn is
abrogated compared to WT DJ-1 (Po0.0001; Figure 3a).
The C106A, E64D and K130R mutations led to a slight but
significant change in DJ-1/aSyn interactions (Figure 3a).
Interestingly, the familial aSyn mutations A30P, E46K and
A53T did not significantly alter the BiFC signal as compared
to WT aSyn (Figure 3b).
Immunoblotting experiments showed that DJ-1 and aSyn
BiFC constructs were highly expressed as WT proteins in
HEK293-transfected cells, as were the mutant aSyn proteins
(A30P, E46K, A53T) and the E64D, K130R and C106A
DJ-1 mutants (Figure 3c). The L166P, M26I, L10P and
P158D DJ-1 mutants were expressed at lower levels, which
is consistent with previous findings showing that certain
forms of mutant DJ-1 are less stable and more rapidly
degraded than the WT protein.17 These data indicate that for
this subset of DJ-1 familial mutations, the decrease in
interactions with aSyn is due – at least in part – to decreased
expression levels, which is likely representative of what
occurs in patients. Nonetheless, these results indicate that
familial mutations in DJ-1 can dramatically abrogate inter-
actions with aSyn in living cells.
DJ-1 modulates aSyn oligomerization. To investigate the
impact of DJ-1 on aSyn oligomerization, WT and mutant
(L10P, M26I, P158D, L166P) DJ-1-myc plasmids were
transiently transfected, along with the mCherry transfection
control plasmid, into H4 cells stably expressing VN-Syn and
Syn-VC. This BiFC model of aSyn dimerization/oligomeriza-
tion was previously described by our group and results in a
clear fluorescence signal distributed throughout the cell5
(Figure 4a). When H4 VN-Syn/Syn-VC cells were transfected
with myc-tagged WT DJ-1, a significant B22% decrease in
the BiFC signal was observed in comparison to cells
transfected with the empty vector control (pcDNA3.1þ )
(Figures 4b and c; Po0.01), indicating a decrease in aSyn
oligomerization because of WT DJ-1. L10P, M26I and P158D
mutant forms of DJ-1 failed to significantly impair aSyn
oligomerization (Figures 4b and c), suggesting that these
DJ-1 mutations lead to a loss of DJ-1 chaperone function.
L166P mutant DJ-1, however, reduced the aSyn BiFC signal
to a similar extent as WT DJ-1 (Figures 4b and c; Po0.05).
Expression of the transfected DJ-1 constructs was
confirmed by immunoblotting (Figure 4d), supporting the
finding that the familial mutations impair the capability
of DJ-1 to antagonize aSyn dimerization/oligomerization.
Interestingly, the M26I, P158D and L166P mutants were
expressed at levels similar to WT DJ-1, which is in contrast to
our immunoblotting data above as well as past studies that
found decreased stability of these proteins.17 This is likely
because of the N-terminal myc tag stabilizing these proteins,
thereby permitting the direct testing of the effect these
mutations have on aSyn oligomerization, independent of
protein levels. In the case of L10P DJ-1, expression was lower
than the WT DJ-1, which is consistent with previous studies.17
DJ-1 reduces aSyn aggregation and cellular toxicity in
yeast. Since the initial report on aSyn aggregation and
toxicity in budding yeast,9 this organism has been extensively
used to study the mechanisms underlying PD and other
neurodegenerative disorders.27,28 S. cerevisiae has four
genes that belong to the DJ-1 superfamily (HSP31, HSP32,
HSP33, HSP34).29 We found that co-expression of each of
these four yeast genes reduced aSyn toxicity in yeast as
indicated by spotting assays (Figure 5a). To investigate
whether human DJ-1 has the same effect on aSyn toxicity,
we repeated the experiment co-expressing human DJ-1 and
aSyn in yeast. Concordantly, we found that aSyn toxicity is
reduced by human DJ-1 (Figure 5b). Immunoblotting showed
that the protein levels of aSyn did not change in the presence
of the Hsps, demonstrating that the effect on toxicity was not
simply because of decreased levels of aSyn in the cell
(Figure 5c). Next, we performed a sucrose velocity gradient
assay to separate proteins according to their molecular
weight, as we previously described.30 Overexpression of all
the DJ-1 superfamily members reduced the high molecular
weight aSyn species (Figure 5d). This was further corrobo-
rated by counting the number of cells with aSyn inclusions by
fluorescence microscopy (Figures 5e and f). We observed a
B15% reduction in the number of cells with inclusions when
the Hsps were co-expressed (Po0.01), which is in agree-
ment with our data obtained in mammalian cells showing that
DJ-1 modulates aSyn oligomerization.
Discussion
aSyn plays an important role in the pathogenesis of several
neurodegenerative diseases including PD and dementia with
Lewy bodies.31–34 Indeed, aggregated aSyn is the major
component of Lewy bodies, protein inclusions that are found
in the brains of PD and DLB patients.31 Moreover, mutations in
or increased dosage of the aSyn-encoding gene lead to
autosomal dominant familial PD. However, whether aSyn
aggregation per se is cytotoxic and causes neurodegeneration,
or the aggregation is an attempt to shield the neurons from toxic
aSyn molecules of lower order, is still controversial.3,5,35–38
DJ-1 is a ubiquitously expressed protein known to regulate the
cellular response to oxidative stress by various mechanisms,
including regulation of gene expression and mitochondrial
integrity, induction of survival pathways and protein refold-
ing.12,19,22,39–42 Mutations in the gene encoding DJ-1 can
cause autosomal recessive PD,1,43 although the underlying
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pathology leading to the development of PD is complex and
various mechanisms are thought to be involved.31,44,45 Indeed,
mitochondrial impairment and oxidative stress as well as
protein misfolding are key events, but it is still not clear whether
they are a cause or a consequence of the disease process.
DJ-1 has been found to be involved in these pathways in a
neuroprotective manner. In line with our findings, DJ-1 has
been shown to prevent protofibril formation by monomeric
aSyn in vitro19 and reduce aSyn aggregation and toxicity.22 In
addition, we also recently found that DJ-1 modulates mutant
huntingtin aggregation in vitro and in vivo, in different models
of Huntington’s disease.46 In all of the reported studies, the
chaperone-like activity of DJ-1 was dependent on the
oxidative environment46 and, in particular, on the oxidation
state of C106.47 Complementing these observations, our
experiments find that the interaction of C106A mutant DJ-1
and aSyn is significantly impaired, further supporting the
importance of the oxidation state of this residue for DJ-1
function and activation. Furthermore, DJ-1 has been found to
bind copper ions at C106, which under critical conditions can
be transferred to SOD1 (superoxide dismutase 1), thereby
activating its catalytic function.48 This is thought to take place
via a direct copper chaperone-like interaction between DJ-1
and SOD1.49
On the basis of the finding that DJ-1 prevents aSyn fibril
formation,19 many reasoned that a direct interaction between
the two proteins was likely to take place. However, previous
attempts have failed to show a direct interaction between DJ-1
and aSyn,50 possibly because of the need of additional
cofactors to stabilize the interaction. Therefore, our study
demonstrates for the first time that DJ-1 and aSyn can
directly interact in vitro and in living cells. As both the BiFC
assay and our in vitro approaches demonstrate an interaction
of DJ-1 with monomeric aSyn, our work is consistent with the
idea that the DJ-1-aSyn interaction is an early event in the
aSyn aggregation process.19
Figure 3 Familial PD DJ-1 mutations decrease DJ-1/aSyn interactions in living cells. (a) Effect of L166P, E64D, M26I, L10P, P158D, K130R and C106A DJ-1 mutations
on the efficiency of fluorescence complementation between DJ-1 and aSyn BiFC constructs. The histogram shows the average ratio intensity (Green/Red) þ S.E.M. per well.
All the investigated DJ-1 mutations constrain the interaction efficiency of DJ-1 with aSyn significantly as indicated by decreased fluorescence intensity ratios compared to the
DJ-1 (WT)/aSyn (WT) combination. ****Po0.0001. (b) Effect of A30P, E46K and A53T aSyn mutations on the efficiency of fluorescence complementation between DJ-1 and
aSyn BiFC constructs. The histogram shows the average ratio intensityþ S.E.M. per well. The ratio intensity of the BiFC signal from HEK293 cells co-transfected with VN-Syn
(WT and mutants) and DJ-1(WT)-CFPC are not significantly different from one another, indicating that familial aSyn mutations (A30P, E46K, A53T) do not impair the
interaction of aSyn with DJ-1. (c) Immunoblots of the lysates obtained from the transfected cell populations used in A. Upper panel: anti DJ-1 antibody, Middle panel: anti aSyn
antibody, Lower panel: anti Tubulin (left panel); anti b-actin antibody (right panel)
Figure 2 DJ-1 interacts with aSyn in living cells. (a) Schematic representation of the BiFC assay. The interaction of two proteins of interest (DJ-1 and aSyn) tagged with
non-fluorescent fragments of fluorescent proteins (Venus or CFP) drives the reconstitution of the functional fluorophore resulting in fluorescence emission. (b) Representative
sections showing the fluorescence complementation signal of DJ-1-GFPN/DJ-1-CFPC, VN-Syn/Syn-VC, VN-Syn/DJ-1-CFPC and Syn-VC/DJ-1-GFPN in living cells. Scale
bar: 100mm. The distribution of ratios between GFP and mCherry emissions in individual cells co-transfected with plasmids encoding the proteins is shown in each graph.
(c) The histogram shows the average ratio intensity for the indicated plasmid combinations (þ S.E.M.). The combinations of the BiFC constructs DJ-1-GFPN/DJ-1-CFPC,
VN-Syn/Syn-VC and VN-Syn/DJ-1-CFPC result in a fluorescence complementation signal indicated by positive intensity ratios when normalized to the mCherry transfection
control. The same constructs combined with an empty vector control (3.1þ ) or transfection of the empty vector control alone do not result in positive fluorescence intensity
ratios, indicating that fluorescence is only caused by the interaction of the two complementary constructs. (d) Immunoblotting analysis of the protein lysates obtained from
transfected cell populations used in the BiFC experiment show the expression of the tested BiFC constructs, Upper panel: anti DJ-1 antibody, Middle panel: anti aSyn antibody,
Lower panel: anti b-actin antibody
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As mutations in the genes encoding these two proteins are
implicated in familial PD,1 we hypothesized that these familial
mutations could affect the interaction between the two
proteins. Indeed, we demonstrate that familial PD mutations
of DJ-1 affect this interaction. Furthermore, we show that DJ-1
reduces aSyn dimerization whereas familial PD mutant
versions of DJ-1 fail to antagonize aSyn dimerization to the
same degree. The mechanisms by which DJ-1 mutations
cause the disease are not known, and an impairment of the
interaction between DJ-1 and aSyn could provide a
mechanistic explanation. Interestingly, the familial aSyn
mutations interrogated in our study (A30P, E46K, A53T) did
not abrogate interactions with WT DJ-1 by BiFC. To date,
protein–protein interactions of aSyn have mostly been
investigated in terms of aggregation (e.g. aggregation with
tau or Ab)51,52 or membrane association,53 but not regarding
potentially neuroprotective players in the PD context.
In contrast to the familial aSyn mutations, familial DJ-1
mutations – particularly L166P, M26I, L10P and P158D – were
found to abrogate the interaction between DJ-1 and aSyn. These
mutations impair DJ-1 homodimerization,17,54,55 suggesting that
the functionality of the protein is perturbed. Moreover, these
mutants increase the degradation and turnover rate of
DJ-1,17,54,55 which explains the lower protein levels detected in
these experiments. Our data suggest that the recessive familial
mutations that impair dimerization and protein stability of DJ-1
also hinder the interaction between DJ-1 and aSyn, which is in
agreement with several familial PD mutations affecting normal
DJ-1 function. Notably, E64D DJ-1 is stable and dimerizes in a
manner similar to WT17 and it is thus still unclear how this
mutation might cause PD; our results show, however, that the
E64D mutation restrains the interaction of DJ-1 with aSyn. The
C106A mutation abolishes DJ-1 oxidation at this residue, which
has been shown to be crucial for its chaperone activity.47
Therefore, our finding that the interaction of C106A DJ-1 with
aSyn is significantly decreased compared to WT DJ-1 supports
the hypothesis that DJ-1 acts as a chaperone on misfolded
aSyn. As the K130R mutation – which prevents DJ-1
SUMOylation – also impairs the interaction with aSyn, the
chaperone-like activity of DJ-1 may not only be dependent on
oxidation but also upon SUMOylation.
As aSyn misfolds and aggregates in PD, and DJ-1 displays
chaperone-like functions,19,46,49 we hypothesized that DJ-1
may modulate aSyn aggregation. Thus, we investigated the
effect of DJ-1 on aSyn oligomerization using BiFC and
observed that WT DJ-1 significantly reduces aSyn oligomer-
ization in living cells. Our findings support previous studies
that found DJ-1 prevented aSyn protofibril formation from
monomeric aSyn19 and reduced aSyn aggregation.47 Taken
together, these results suggest that DJ-1 may prevent aSyn
aggregation by interfering with the initial steps in the
aggregation process of di- or oligomerization. L10P, M26I
Figure 4 DJ-1 modulates aSyn oligomerization. (a) Schematic representation of the BiFC model of aSyn oligomerization used in this experiment. H4 cells stably
expressing VN-Syn/Syn-VC were used to examine the impact of transiently transfected DJ-1 on aSyn oligomerization. (b) The impact of DJ-1 (WT and mutants, as indicated in
the graphs) on aSyn oligomerization was examined. The distribution of intensity ratios between Venus and mCherry emissions in individual cells transiently transfected with the
plasmid encoding myc-tagged DJ-1 (WT or mutant) or an empty vector control (3.1þ ) together with the mCherry control plasmid is shown in each graph. (c) The histogram
shows the average ratio intensityþS.E.M. per well. A decrease was observed when VN-aSyn/aSyn-VC expressing H4 cells were transfected with DJ-1 (WT) compared to the
empty vector control 3.1þ (Po0.01) indicating that WT DJ-1 interferes with aSyn oligomerization. DJ-1 mutants (L10P, M26I, P158D) failed to impair aSyn oligomerization to
the same degree, while the L166P mutant significantly decreased the BiFC signal (Po0.05). (d) Immunoblot confirming the expression of transfected myc-DJ-1 constructs, as
well as the stable expression of VN-Syn and Syn-VC. Upper panel: anti DJ-1 antibody, Middle panel: anti aSyn antibody, Lower panel: anti b-actin antibody
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and P158D DJ-1 are unable to decrease aSyn dimerization,
clearly suggesting a loss of the chaperone DJ-1 function in
these mutants. Unexpectedly, the L166P DJ-1 mutant
significantly reduced aSyn oligomerization. Notably, the
L166P protein is highly expressed in these experiments, likely
as a result of protein stabilization because of the N-terminal
myc tag. This suggests that this stabilized form of L166P is
functional, and thereby is able to modulate aSyn aggregation.
Our findings in yeast, with human DJ-1 as well as the four
yeast DJ-1 orthologs, further suggest that the chaperone
function of DJ-1 is beneficial, as aSyn toxicity was ameliorated
alongside with a reduction in aggregation.
In summary, we provide the first evidence that a direct
interaction between aSyn and DJ-1 could be an important
neuroprotective mechanism in the context of PD, and that the
disruption of these interactions can contribute to the pathology
Figure 5 DJ-1 suppresses aSyn toxicity and aggregation in yeast. (a) Spotting assay of yeast cultures co-expressing aSyn and Hsp31, Hsp32, Hsp33 or Hsp34. Cultures were
adjusted to OD600 nm¼ 0.1, fivefold serially diluted and spotted onto media plates containing either glucose (aSyn and Hsps expression is repressed, ‘OFF’) or galactose (expression is
induced, ‘ON’). The spotting assay demonstrates that aSyn expression significantly reduces yeast growth and that co-expression of Hsp31, Hsp32, Hsp33 and Hsp34 reverses this
toxicity. (b) Spotting assay of yeast cultures expressing aSyn and/or DJ-1. Cultures were adjusted to OD600 nm¼ 0.1, fivefold serially diluted and spotted onto media plates to observe
aSyn toxicity. This spotting assay confirms that aSyn expression significantly reduces yeast growth and that co-expression of human DJ-1 reverses the toxicity. (c) Immunoblotting
demonstrates the expression levels of aSyn-GFP, Hsp31, Hsp32, Hsp33, and Hsp34 after 7 h of induction of aSyn expression. PGK was used as loading control. (d) Co-expression of
aSyn with Hsp31, Hsp32, Hsp33 or Hsp34 reduces the high molecular weight aSyn species formed in yeast as analyzed by a sucrose velocity gradient and subsequent immunoblotting
7 h after induction of aSyn expression. (e) Representative images showing the intracellular localization of aSyn-GFP expressed alone or with Hsp31, Hsp32, Hsp33 or Hsp34. Scale
bar: 5mm. (f) The histogram shows the mean percentage of yeast cells containing aSyn inclusionsþ S.E.M., assessed by fluorescence microscopy 7 h after induction of aSyn
expression. Co-expression of Hsp31, Hsp32, Hsp33 or Hsp34 significantly decreases the number of aSyn inclusions (Po0.05)
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caused by DJ-1 mutations. These observations support the
notion that pharmacological interventions aimed at enhancing
DJ-1 activity may provide a relevant therapeutic option in PD
and in other synucleinopathies.
Materials and Methods
Immunoprecipitation of aSyn monomers and oligomers. HEK293
cells were transiently transfected by Neon (Invitrogen, Carlsbad, CA, USA) with
myc-DJ-1 using 7.5mg DNA and 1100 mV for 20 ms, 2 pulses. After 24 h, the cells
were trypsinized, collected by centrifugation, washed in Hank’s buffered salt
solution (HBSS) and lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Triton
X-100, 2 mM EDTA, 0.5% DOC, 0.1% SDS, Complete protease inhibitor
cocktail mix, Roche, Basel, Switzerland). aSyn oligomers were produced by
incubation of 10 mg/ml recombinant aSyn in phosphate-buffered saline (PBS) for
30 min on ice and isolated by gel filtration as previously described.23 2mg of aSyn
oligomers or monomers were mixed with 1.5 mg/ml HEK myc-DJ-1 lysate in
PBSþ 0.5% TX-100 and allowed to interact over night at 4 1C with rotation. 2% of
input sample was isolated prior to addition of 30ml CNBr-sepharose coupled to
anti-aSyn (ASY-1), an affinity purified rabbit antibody against human aSyn as
previously described.56 Samples were incubated at 4 1C with rotation for 2 h.
Sepharose beads were isolated by centrifugation at 1500 r.p.m. for 1 min at 4 1C
and washed five times in PBSþ 0.5% TX-100. Elution was obtained by adding
non-reducing SDS-PAGE loading buffer (50 mM tris pH 6.8, 4% SDS, 40%
glycerol, bromphenol blue) and incubated at 37 1C for 30 min followed by
centrifugation. Diethyl ether (DTE) was added to the supernatant to the final
concentration of 20 mM. Then the mixture was heated at 95 1C for 5 min and
subsequently subjected to 10–16% SDS-PAGE and immunoblotted on a PVDF
membrane (HYBOND LFP PVDF transfer membrane, GE Healthcare, Chalfont
St Giles, UK; #RPN303LFP) using the primary antibodies rabbit anti-DJ-1
(1 : 2000, Abcam, Cambridge, UK; #ab18257) and rabbit anti-aSyn (1 : 1000,
described above), as well as HRP conjugated secondary antibodies (1 : 1000,
Dako, Glostrup, Denmark).
Immunoprecipitation of endogenous aSyn and DJ-1. C57BL/6 WT
mouse (6 months of age) brain homogenate was prepared in RIPA buffer. After
retrieving the 10% input sample, the brain homogenate was incubated with 25 ml
CNBr-sepharose beads (GE Healthcare, #17-0430-01) coupled to anti-aSyn (ASY-
1) or non-immune rabbit IgG (4 mg IgG/ml swelled sepharose) at 4 1C with rotation
for two hours. Then, the beads were isolated, washed, eluted and immunoblotted
as described above using the primary antibodies rabbit anti-DJ-1 (1 : 2000, Abcam
#ab18257) and mouse anti-aSyn (1 : 1000, BD #610787, Franklin Lakes, NJ, USA)
and polyclonal swine anti-rabbit IgG and polyclonal rabbit anti-mouse IgG HRP
conjugated secondary antibodies (1 : 1000, Dako # P0217 and #P0260).
Cell culture. HEK293 cells were cultured in DMEM high glucose, supplemented
with 10% fetal calf serum (FCS), 100 units/ml penicillin and 100mg/ml streptomycin;
H4 cells were grown in OPTI-MEM, supplemented with 10% FCS, 100 units/ml
penicillin and 100mg/ml streptomycin. H4 cells stably transfected with two plasmids
encoding aSyn tagged with either the N-terminal part or the C-terminal portion of
Venus protein5 were cultured in OPTI-MEM with 30% FCS, 100 units/ml penicillin,
100mg/ml streptomycin and 0.1% G418. All cells were grown at 37 1C in 95% air /
5% CO2 atmosphere. For BiFC experiments, cells were grown on 6-well plates
(1.5 105 cells/well) pre-coated with 0.01% Poly-L-lysine solution or on 24-well
plates at a density of 1 104 cells/well 24 h prior to transfection.
Generation of DNA constructs. The aSyn BiFC constructs (VN-Syn,
Syn-VC, VN-Syn(A30P), VN-Syn (E46K), VN-Syn(A53T)) have been previously
used in our laboratory,5 as well as the DJ-1 BiFC constructs (DJ-1-CFPC,
DJ-1-GFPN, DJ-1(L10P)-CFPC, DJ-1(M26I)-CFPC, DJ-1(E64D)-CFPC,
DJ-1(P158D)-CFPC, DJ-1(L166P)-CFPC)).17 The DJ-1(C106A)-CFPC and
the DJ-1(K130R)-CFPC constructs were produced as described previously:17
the primer sequences are listed in the Supplementary Information;
(Supplementary Table S1). To introduce the four different familial point
mutations L10P, M26I, P158D and L166P into a DJ-1-myc plasmid vector
(pGW1-CMV vector backbone), the QuickChange Site-Directed Mutagenesis
kit (Stratagene, La Jolla, CA, USA) was employed according to manufacturer
protocols using the primers listed in Supplementary Information;
(Supplementary Table S2). All constructs were verified by DNA sequencing.
BiFC assays. HEK293 cells were transfected with combinations of DJ-1 and
aSyn-BiFC constructs using either Metafectene (Biontex, Munich, Germany) or
Effectene (Qiagen, Venlo, Netherlands). Additionally, a transfection control
plasmid encoding the red fluorescent mCherry protein or RFP was included in all
experiments, allowing the selection of successfully transfected cells. The amount
of the mCherry/RFP plasmid comprised one-fifth of the total DNA amount per well,
whereas the BiFC constructs were used in equal amounts. The total DNA amount
per well was 0.25mg in a 24-well plate format and 0.4mg in a 6-well plate format.
To ensure optimal reconstitution of the fluorophores, particularly GFP, the
transfected cells were incubated at 30 1C overnight prior to the image acquisition
at the microscope. To explore the effect of DJ-1 on aSyn oligomerization, a BiFC-
based aSyn dimerization/oligomerization model developed in our laboratory5 was
used. H4 neuroglioma cells stably transfected with Venus-tagged aSyn BiFC
constructs were transiently transfected with myc-DJ-1 plasmids using FuGene6
(Promega, Madison, WI, USA), including the same mCherry control plasmid as
mentioned above. The total DNA amount per well was 0.5mg.
Microscopy. Cells were imaged 24 h (H4 cells) or 48 h (HEK293 cells) post
transfection with an Olympus XI81 system (Olympus Soft Imaging Solutions
GmbH, Mu¨nster, Germany) or with an Olympus ScanˆR screening station equipped
with a 20 LUCPlanFLN objective (NA¼ 0.45) and a Hamamatsu ORCA-AG
CCD camera (Hamamatsu Photomics, Hamamatsu, SZK, Japan). The light source
was a MT-20 illumination system (Olympus Soft Imaging Solutions GmbH) with a
high-stability 150 W xenon short arc burner. During imaging the cells were kept at
37 1C and 5% CO2. GFP/Venus BiFC fluorescence was detected using a 470/
22 nm excitation filter and a 535/50 nm emission filter. mCherry/RFP expression
was imaged using excitation at 556/20 nm and emission between 590 and 650 nm
using the filter set 51019 (Chroma, Bellow Falls, VT, USA). In 24-well format
experiments, 25 pictures were taken per well and about 800–1500 cells were
identified to be mCherry positive for each condition in each independent
experiment. The ratio between GFP/Venus and mCherry emission intensities was
quantified for every cell expressing mCherry after subtraction of the background
signal using the ScanˆR analysis software as previously described.17 In 6-well
format experiments, 100 pictures were taken per well. All experiments were
performed in duplicate (6-well format) or triplicate (24-well format) and repeated
three times. To obtain higher magnification representative images for each of the
transfection combinations, transfected cells were fixed with 4% PFA in PBS (PAN)
for 10 min at RT. After a washing step with PBS, cells were incubated for 10 min at
RT in Hoechst 33258 (Molecular Probes, Carlsbad, CA, USA) solution for nuclear
staining and then kept in PBS until used for microscopy. Representative images
were taken with a Leica epifluorescence microscope (Leica, Wetzlar, Germany)
using a 40 objective.
Immunoblotting of BiFC cell experiments. Directly after image
acquisition at the microscope, cells were washed twice with sterile PBS and
then lysed on ice for 10 min in lysis buffer as previously described17 or RIPA buffer
(50 mM Tris, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 0.5% DOC, 0.1% SDS,
complete protease inhibitor cocktail mix, Roche). Lysates were centrifuged at
13 000 r.p.m. for 10 min at 4 1C. Supernatants were collected and protein
concentration was determined by the Bradford method. Samples were stored at
 80 1C until used. 10 to 30mg of protein per slot were separated on a 12% SDS
polyacrylamide gel and transferred to a polvinylidene difluoride membrane.
Membranes were incubated for 1 h in TBST (50 mM Tris, 150 mM NaCl, 0.05%
Tween, pH 7.5) containing 5% milk to saturate all non-specific binding sites.
Incubation with primary antibodies was overnight at 4 1C in 1% milkþ TBST
(1 : 1500 goat anti-DJ-1, Santa Cruz Biotechnology, Dallas, TX, USA; #Sc-27006;
1 : 3000 mouse anti-a-Synuclein, BD #610787; 1 : 5000 mouse anti-b-actin,
Sigma-Aldrich, St. Louis, MO, USA; #A5441). Blots were developed using
horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-goat
1 : 10 000 Jackson Immunoresearch, West Grove, PA, USA; #705-035-003,
anti-mouse 1 : 10 000 Sigma #50185-ILM-F) and the Immobilon chemiluminescent
HRP substrate (Millipore, Billerica, MA, USA).
Yeast plasmids, strains and culture conditions. Yeast work was
performed in the wild-type BY4714 background (MAT, ura3D0, leu2D0, his3D1,
met15D0). The yeast expression vector p426GAL was used to express human
SNCA fused with GFP under a galactose-inducible promoter (GAL1) as previously
described.9 Hsp31, Hsp32, Hsp33 or Hsp34 fused to a 6xHis-HA tag, were
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expressed under control of the GAL1 promoter with BG1805 plasmids (Thermo
Scientific, Waltham, MA, USA). To express the human DJ-1 gene under the
regulation of the constitutive promoter TPI, the yeast vector pYX212 DJ-1 was
used. Yeast cultures were transformed using a standard lithium acetate protocol.
All strains were grown in synthetic complete medium without uracil and histidine
(SC–URA-HIS), 6.7 g/l Yeast Nitrogen Base (BD), appropriate amino acid dropout
mix (Sunrise Science Products, San Diego, CA, USA), 1% (w/v) raffinose or 1%
(w/v) galactose. Yeast cells carrying the galactose-inducible aSyn-GFP construct
alone or in combination with empty vector, Hsp31, Hsp32, Hsp33 or Hsp34 were
pre-grown in SC-URA-HIS 1% raffinose for 24 h and then diluted back in order to
reach an optical density (OD600 nm) of 0.4. For growth assays on solid medium, the
cultures were serially diluted and spotted on SC-URA-HIS containing 1%
galactose or 1% glucose (control) agar plates, which were then incubated at 30 1C
for at least 48 h. For microscopy studies or protein extraction aSyn expression was
induced in SC-URA-HIS 1% galactose for 7 h.
Yeast protein extraction and immunoblotting. For total protein
extraction, yeast cells were lysed in MURB buffer (50 mM sodium phosphate,
25 mM MES, pH 7.0, 1% SDS, 3 M urea, 0.5% 2-mercaptoethanol, 1 mM sodium
azide) supplemented with protease and phosphatase inhibitor cocktail (Roche),
with glass beads, three cycles of 30 s in the bead beater and 5 min on ice. Cell
debris was removed by centrifugation at 10 000 g for 1 min at room temperature
and after denaturation at 70 1C, the supernatant was collected. Equal volumes of
total protein were analyzed by SDS-PAGE for the detection of aSyn levels. After
electrophoresis, samples were transferred to a nitrocellulose membrane using a
Trans-Blot Turbo transfer system (Bio-Rad, Hercules, CA, USA). Immunoblotting
was performed following standard procedures with antibodies against aSyn
(1 : 5000, BD #S63320), PGK (1 : 1000, Life Technologies Corporation, Carlsbad,
CA, USA; #459250) and HA (1 : 1000, Santa Cruz Biotechnology #sc-7392).
Sucrose gradient analysis of aggregation. Total protein from cells
expressing WT or S129A aSyn was obtained and applied on a 5–30% sucrose
gradient as previously described.30 Fractions were collected, precipitated for 4 h at
4 1C in trichloroacetic acid, washed in acetone three times and suspended in
protein sample buffer (0.5 M Tris-HCl, pH 6.8, glycerol, 10% (w/v) SDS, 0.1% (w/v)
bromophenol blue). Proteins were resolved by SDS-PAGE and estimation of the
molecular sizes for each fraction were performed as previously described.57
Yeast fluorescence microscopy. The percentage of cells with aSyn
inclusions was determined by fluorescence microscopy using a Zeiss Axiovert
200 M (Carl Zeiss, Jena, Germany) wide-field fluorescence microscope equipped
with a cooled CCD camera (Roper Scientific Coolsnap HQ, Martinsried, Germany)
and a 63 objective to acquire images containing at least 500 cells per strain,
which were then counted using ImageJ. Yeast cells were grown as described
above. After 7 h of induction, cells were collected by centrifugation and
resuspended in PBS and 0.5% low melting agarose on a microscope slide.
Statistical analyses. BiFC data were analyzed using the Mann–Whitney
non-parametric test (GraphPad Prism 6), whereas yeast data were analyzed by
the Tukey HSD (Honest Significant Difference) multiple comparison test
(a¼ 0.05). All data are reported as the mean± standard error of the mean
(S.E.M.). Data were considered significant when Pr0.05. * indicates Pr0.05,
** indicates Pr0.01, *** indicates Pr0.001 and **** indicates Pr0.0001.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This work was supported by funding from Parkinson’s
UK (Research Grant G-0902), Fundac¸a˜o Calouste Gulbenkian and by Fundac¸a˜o
para a Cieˆncia e Tecnologia project PTDC/BIA-BCM/117975/2010, and fellowships
SFRH/BPD/35767/2007 (ST), SFRH/BD/36065/2007 (LMF), SFRH/BD/79337/
2011 (SG) and IMM/BTI/91-2012 (RRR). TFO was also supported by an EMBO
Installation Grant and by the DFG Center for Nanoscale Microscopy and Molecular
Physiology of the Brain (CNMPB).
1. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC et al.
DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci
2003; 24: 159–160.
2. Marques O, Outeiro TF. Alpha-synuclein: from secretion to dysfunction and death. Cell
Death Dis 2012; 3: e350.
3. Wales P, Pinho R, Lazaro DF, Outeiro TF. Limelight on alpha-synuclein: pathological and
mechanistic implications in neurodegeneration. J Parkinsons Dis 2013; 3: 415–459.
4. Paleologou KE, El-Agnaf OM. alpha-Synuclein aggregation and modulating factors.
Subcell Biochem 2012; 65: 109–164.
5. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F et al. Formation of
toxic oligomeric alpha-synuclein species in living cells. PloS One 2008; 3: e1867.
6. Winkler S, Hagenah J, Lincoln S, Heckman M, Haugarvoll K, Lohmann-Hedrich K et al.
alpha-Synuclein and Parkinson disease susceptibility. Neurology 2007; 69:
1745–1750.
7. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B et al. Alpha-synuclein
blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science
2006; 313: 324–328.
8. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ et al. The Parkinson’s
disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA
2008; 105: 145–150.
9. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and
pathobiology. Science 2003; 302: 1772–1775.
10. Fasano M, Lopiano L. Alpha-synuclein and Parkinson’s disease: a proteomic view. Expert
Rev Proteomics 2008; 5: 239–248.
11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-
synuclein in Lewy bodies. Nature 1997; 388: 839–840.
12. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S et al.
The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven
mitochondrial localization. Proc Natl Acad Sci USA 2004; 101: 9103–9108.
13. Blackinton J, Ahmad R, Miller DW, van der Brug MP, Canet-Aviles RM, Hague SM et al.
Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular
localization. Brain Research Mol Brain Res 2005; 134: 76–83.
14. Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI et al. Mitochondrial
localization of the Parkinson’s disease related protein DJ-1: implications for pathogenesis.
Hum Mol Genet 2005; 14: 2063–2073.
15. Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA. The 1.1-A resolution crystal structure
of DJ-1, the protein mutated in autosomal recessive early onset Parkinson’s disease.
Proc Natl Acad Sci USA 2003; 100: 9256–9261.
16. Gorner K, Holtorf E, Waak J, Pham TT, Vogt-Weisenhorn DM, Wurst W et al. Structural
determinants of the C-terminal helix-kink-helix motif essential for protein stability and
survival promoting activity of DJ-1. J Biol Chem 2007; 282: 13680–13691.
17. Repici M, Straatman KR, Balduccio N, Enguita FJ, Outeiro TF, Giorgini F. Parkinson’s
disease-associated mutations in DJ-1 modulate its dimerization in living cells. J Mol Med
(Berl) 2013; 91: 599–611.
18. Cookson MR. DJ-1, PINK1, and their effects on mitochondrial pathways. Mov Disord 2010;
25: S44–S48.
19. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent
molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004;
2: e362.
20. Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, Freed CR. Phenylbutyrate
up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of
Parkinson disease. J Biol Chem 2011; 286: 14941–14951.
21. Sun SY, An CN, Pu XP. DJ-1 protein protects dopaminergic neurons against
6-OHDA/MG-132-induced neurotoxicity in rats. Brain Research Bull 2012; 88: 609–616.
22. Zhou W, Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and
inhibits A53T alpha-synuclein toxicity. J Biol Chem 2005; 280: 43150–43158.
23. Mysling S, Betzer C, Jensen PH, Jorgensen TJ. Characterizing the dynamics of
alpha-synuclein oligomers using hydrogen/deuterium exchange monitored by mass
spectrometry. Biochemistry 2013; 52: 9097–9103.
24. Goncalves SA, Matos JE, Outeiro TF. Zooming into protein oligomerization in
neurodegeneration using BiFC. Trends Biochem Sci 2010; 35: 643–651.
25. Hu CD, Kerppola TK. Simultaneous visualization of multiple protein interactions in living
cells using multicolor fluorescence complementation analysis. Nat Biotechnol 2003; 21:
539–545.
26. Honbou K, Suzuki NN, Horiuchi M, Niki T, Taira T, Ariga H et al. The crystal structure of
DJ-1, a protein related to male fertility and Parkinson’s disease. J Biol Chem 2003; 278:
31380–31384.
27. Miller-Fleming L, Giorgini F, Outeiro TF. Yeast as a model for studying human
neurodegenerative disorders. Biotechnol J 2008; 3: 325–338.
28. Tenreiro S, Munder MC, Alberti S, Outeiro TF. Harnessing the power of yeast to unravel the
molecular basis of neurodegeneration. J Neurochem 2013; 127: 438–452.
29. Wilson MA, St Amour CV, Collins JL, Ringe D, Petsko GA. The 1.8-A resolution crystal
structure of YDR533Cp from Saccharomyces cerevisiae: a member of the DJ-1/ThiJ/PfpI
superfamily. Proc Natl Acad Sci USA 2004; 101: 1531–1536.
30. Basso E, Antas P, Marijanovic Z, Goncalves S, Tenreiro S, Outeiro TF. PLK2 modulates
alpha-synuclein aggregation in yeast and mammalian cells. Mol Neurobiol 2013; 48:
854–862.
DJ-1 interacts with aSyn
L Zondler et al
9
Cell Death and Disease
31. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an
aggresome-related process: a hypothesis. Lancet Neurol 2004; 3: 496–503.
32. Bonini NM, Giasson BI. Snaring the function of alpha-synuclein. Cell 2005; 123: 359–361.
33. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of
alpha-synuclein in neurological disorders. Lancet Neurol 2011; 10: 1015–1025.
34. Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A et al. Direct observation of
the interconversion of normal and toxic forms of alpha-synuclein. Cell 2012; 149:
1048–1059.
35. Brown DR. Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life 2010; 62:
334–339.
36. Celej MS, Sarroukh R, Goormaghtigh E, Fidelio GD, Ruysschaert JM, Raussens V. Toxic
prefibrillar alpha-synuclein amyloid oligomers adopt a distinctive antiparallel beta-sheet
structure. Biochem J 2012; 443: 719–726.
37. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic
alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy
in vivo. J Neurosci 2012; 32: 3301–3305.
38. Roostaee A, Beaudoin S, Staskevicius A, Roucou X. Aggregation and neurotoxicity of
recombinant alpha-synuclein aggregates initiated by dimerization. Mol Neurodegener
2013; 8: 5.
39. Fan J, Ren H, Jia N, Fei E, Zhou T, Jiang P et al. DJ-1 decreases Bax expression through
repressing p53 transcriptional activity. J Biol Chem 2008; 283: 4022–4030.
40. Aleyasin H, Rousseaux MW, Marcogliese PC, Hewitt SJ, Irrcher I, Joselin AP et al.
DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT
pathway. Proc Natl Acad Sci USA 2010; 107: 3186–3191.
41. Irrcher I, Aleyasin H, Seifert EL, Hewitt SJ, Chhabra S, Phillips M et al. Loss of the
Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet
2010; 19: 3734–3746.
42. Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson’s disease-associated
DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction.
J Neurochem 2012; 121: 830–839.
43. van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ
et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on
chromosome 1p36. Am J Hum Genet 2001; 69: 629–634.
44. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of
alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 2013; 14: 626–636.
45. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013; 19:
983–997.
46. Sajjad MU, Green EW, Miller-Fleming L, Hands S, Herrera F, Campesan S et al. DJ-1
modulates aggregation and pathogenesis in models of Huntington’s disease. Hum Mol
Genet 2014; 23: 755–766.
47. Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL. The oxidation state of DJ-1 regulates its
chaperone activity toward alpha-synuclein. J Mol Biol 2006; 356: 1036–1048.
48. Girotto S, Cendron L, Bisaglia M, Tessari I, Mammi S, Zanotti G et al. DJ-1 is a copper
chaperone acting on SOD1 activation. J Biol Chem 2014; 289: 10887–10899.
49. Yamashita S, Mori A, Kimura E, Mita S, Maeda Y, Hirano T et al. DJ-1 forms
complexes with mutant SOD1 and ameliorates its toxicity. J Neurochem 2010; 113:
860–870.
50. Jin J, Li GJ, Davis J, Zhu D, Wang Y, Pan C et al. Identification of novel proteins associated
with both alpha-synuclein and DJ-1. Mol Cell Proteomics 2007; 6: 845–859.
51. Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Goncalves SA, Pera M et al.
Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleino-
pathy. PLoS One 2011; 6: e26609.
52. Jellinger KA. Interaction between alpha-synuclein and other proteins in neurodegenerative
disorders. ScientificWorldJournal 2011; 11: 1893–1907.
53. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K et al.
Direct membrane association drives mitochondrial fission by the Parkinson disease-
associated protein alpha-synuclein. J Biol Chem 2011; 286: 20710–20726.
54. Malgieri G, Eliezer D. Structural effects of Parkinson’s disease linked DJ-1 mutations.
Protein Sci 2008; 17: 855–868.
55. Ramsey CP, Giasson BI. L10p and P158DEL DJ-1 mutations cause protein
instability, aggregation, and dimerization impairments. J Neurosci Res 2010; 88:
3111–3124.
56. Jensen PH, Islam K, Kenney J, Nielsen MS, Power J, Gai WP. Microtubule-associated
protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments.
J Biol Chem 2000; 275: 21500–21507.
57. Tanese N. Small-scale density gradient sedimentation to separate and analyze
multiprotein complexes. Methods 1997; 12: 224–234.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 3.0 Unported License.
The images or other third party material in this article are included in
the article’s Creative Commons license, unless indicated otherwise in
the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the
license holder to reproduce thematerial. To view a copy of this license,
visit http://creativecommons.org/licenses/by/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
DJ-1 interacts with aSyn
L Zondler et al
10
Cell Death and Disease
